88 related articles for article (PubMed ID: 18351210)
21. [Molecular diagnosis of and molecular targeting therapy for leukemia].
Tabe Y
Rinsho Byori; 2009 Feb; 57(2):137-45. PubMed ID: 19317219
[TBL] [Abstract][Full Text] [Related]
22. Haematological malignancies: the rationale for integrated haematopathology services, key elements of organization and wider contribution to patient care.
Ireland R
Histopathology; 2011 Jan; 58(1):145-54. PubMed ID: 21261689
[TBL] [Abstract][Full Text] [Related]
23. [Molecular therapeutics in patients with cancer unresponsive to conventional treatments].
Valdespino-Gómez VM; Valdespino-Castillo VE
Gac Med Mex; 2008; 144(4):333-44. PubMed ID: 18942268
[TBL] [Abstract][Full Text] [Related]
24. Clinical and genetic analysis of unclassifiable inherited bone marrow failure syndromes.
Teo JT; Klaassen R; Fernandez CV; Yanofsky R; Wu J; Champagne J; Silva M; Lipton JH; Brossard J; Samson Y; Abish S; Steele M; Ali K; Athale U; Jardine L; Hand JP; Tsangaris E; Odame I; Beyene J; Dror Y
Pediatrics; 2008 Jul; 122(1):e139-48. PubMed ID: 18595958
[TBL] [Abstract][Full Text] [Related]
25. Plasma-based testing as a new paradigm for clinical testing in hematologic diseases.
Giles FJ; Albitar M
Expert Rev Mol Diagn; 2007 Sep; 7(5):615-23. PubMed ID: 17892367
[TBL] [Abstract][Full Text] [Related]
26. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
[TBL] [Abstract][Full Text] [Related]
27. Recurrence cancer stem cells--made by cell fusion?
Dittmar T; Nagler C; Schwitalla S; Reith G; Niggemann B; Zänker KS
Med Hypotheses; 2009 Oct; 73(4):542-7. PubMed ID: 19564079
[TBL] [Abstract][Full Text] [Related]
28. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract][Full Text] [Related]
29. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.
Caers J; Van Valckenborgh E; Menu E; Van Camp B; Vanderkerken K
Bull Cancer; 2008 Mar; 95(3):301-13. PubMed ID: 18390410
[TBL] [Abstract][Full Text] [Related]
30. Vascular determinants of cancer stem cell dormancy--do age and coagulation system play a role?
Rak J; Milsom C; Yu J
APMIS; 2008; 116(7-8):660-76. PubMed ID: 18834410
[TBL] [Abstract][Full Text] [Related]
31. The insulin-like growth factor-I receptor as an oncogene.
Werner H; Bruchim I
Arch Physiol Biochem; 2009 May; 115(2):58-71. PubMed ID: 19485702
[TBL] [Abstract][Full Text] [Related]
32. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
[TBL] [Abstract][Full Text] [Related]
33. On the karyotypic origin and evolution of cancer cells.
Nicholson JM; Duesberg P
Cancer Genet Cytogenet; 2009 Oct; 194(2):96-110. PubMed ID: 19781442
[TBL] [Abstract][Full Text] [Related]
34. Specific genetic defects as targets for selective therapies. Commentary.
Clarkson B
Curr Opin Hematol; 1994 Jul; 1(4):235-47. PubMed ID: 9371289
[No Abstract] [Full Text] [Related]
35. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
36. Haematological cancers.
Pearce L
Nurs Stand; 2016 Jul; 30(48):15. PubMed ID: 27461299
[TBL] [Abstract][Full Text] [Related]
37. Hematologic malignancies, critical genes and representative pictures for 166 chromosome anomalies.
Mahaffey VJ; Spurbeck JL; Carlson RO; Dewald GW
Leuk Res; 2004 Dec; 28(12):1351-6. PubMed ID: 15475078
[No Abstract] [Full Text] [Related]
38. Advances in understanding the molecular pathogenesis of neoplastic hematologic disorders.
Williams JL
Clin Lab Sci; 2004; 17(4):221-2. PubMed ID: 15559728
[TBL] [Abstract][Full Text] [Related]
39. Clinical applications of molecular genetic testing in hematologic malignancies: advantages and limitations.
Bagg A
Hum Pathol; 2003 Apr; 34(4):352-8. PubMed ID: 12733115
[No Abstract] [Full Text] [Related]
40. Normal and malignant hematopoiesis.
Friedman AD
Oncogene; 2007 Oct; 26(47):6686. PubMed ID: 17934477
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
